A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.

Trial Details

NCT ID
NCT07286266
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Mocertatug rezetecan
  • Paclitaxel
  • Pegylated liposomal doxorubicin (PLD)
  • Topotecan
  • Gemcitabine
  • Pembrolizumab
Locations (sample)
  • Randwick, New South Wales, Australia|-33.91439,151.24895
  • Auchenflower, Queensland, Australia|-27.47443,152.99213
  • Toronto, Ontario, Canada|43.65333,-79.38389
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed…
  • Has epithelial ovarian cancer, inclusive of primary peritoneal or fallopian-tube cancer with a histologically confirmed diagnosis of high grade ser…
  • Platinum-resistance is defined as follows:
  • Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum therapy, must have had a response …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →